(Q41656959)

6 October 2017

1 reference

title

Muromonab-CD3 and antithymocyte globulin in renal transplantation (English)

1 reference

6 October 2017

M L Burk

1

1 reference

6 October 2017

K A Matuszewski

series ordinal

2

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 November 1997

1 reference

Annals of Pharmacotherapy

6 October 2017

published in

1 reference

6 October 2017

volume

31

1 reference

6 October 2017

issue

11

1 reference

6 October 2017

page(s)

1370-1377

1 reference

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101115

Muromonab CD3. A review of its pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101115

The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101115

Two approaches to comparing hospital charges between cadaveric renal transplant patients who received orthoclone OKT 3 sterile solution or Atgam sterile solution for induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101115

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101115

10.1177/106002809703101115

21 January 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference